Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Key Highlights
- ➤Viatris (VTRS) to acquire Pacira (PCRX) for $36.50 per share, valuing equity at $1.65 billion
- ➤Pacira generated approximately $746 million revenue and $177 million adjusted EBITDA in latest twelve months
- ➤Transaction expected to close by end-2026 and immediately accrete Viatris’ financial guidance metrics
- ➤Pacira adds EXPAREL and ZILRETTA, expanding Viatris’ non-opioid pain-therapy portfolio
- ➤Viatris expects to fund deal primarily with excess cash, minimizing gross-leverage impact
Expert Statements
Scott A. Smith, CEO of Viatris
“The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business”
Scott A. Smith, CEO of Viatris
“The addition of EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies, an area where patients and healthcare providers continue to seek more treatment options.”
Scott A. Smith, CEO of Viatris
“Pacira also brings Viatris additional U.S. innovative commercial, market access, medical affairs and global R&D capabilities that are highly complementary to our existing infrastructure and portfolio.”
Scott A. Smith, CEO of Viatris
“This transaction accelerates our path to sustained revenue and earnings growth and adds an innovative development pipeline in certain high-value, specialty-driven therapeutic areas with a high unmet need.”
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller of Viatris
“The proposed transaction is expected to be immediately accretive to our financial guidance metrics”
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller of Viatris
“Importantly, we expect to fund the transaction primarily from excess cash with the remainder from short-term borrowings.”
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller of Viatris
“As such, we expect the transaction will have minimal impact on our gross leverage ratio.”
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller of Viatris
“We believe the transaction is consistent with our disciplined and balanced approach to capital allocation, preserves our financial flexibility and provides opportunities to create additional value through both cost and revenue synergies.”
Frank D. Lee, CEO of Pacira BioSciences
“Our mission from the start has been to deliver innovative, non-opioid pain therapies to transform the lives of patients.”
Frank D. Lee, CEO of Pacira BioSciences
“Pacira has helped reshape pain management by advancing awareness, expanding patient access and driving the adoption of opioid-sparing therapies,”
Frank D. Lee, CEO of Pacira BioSciences
“I am immensely proud of what our team has accomplished, from building a leading commercial portfolio that has helped nearly 20 million patients access non-opioid pain management, to advancing our 5x30 strategy and expanding our innovative pipeline.”
Frank D. Lee, CEO of Pacira BioSciences
“As we enter this next chapter, we are confident that Viatris' shared vision, substantial resources, and global scale will accelerate the impact of our mission and help bring our transformative therapies to even more patients.”
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies PR Newswire
* Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure * Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities * Expected to Be Synergistic With Viatris' Fast-Acting Meloxicam Opportunity * Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris' Financial Guidance Metrics * Transaction Consistent With Viatris' Disciplined and Balanced Capital Allocation Strategy and Preserves Financial Flexibility PITTSBURGH and BRISBANE, Calif. , Oct. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
Get started
Create a free account to read the full story.